Abstracts tagged "Epidemiologic methods"

Abstract Number: 2829 • 2013 ACR/ARHP Annual Meeting
Statin Adherence and Risk Of Mortality In Patients With Rheumatoid Arthritis: A Population-Based Study
Mary De Vera^1,2, Michal Abrahamowicz³ and Diane Lacaille⁴, ¹Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁴Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada
Background/Purpose: Poor adherence with statin therapy is associated with increased mortality in the general population, but no corresponding data are available among patients with rheumatoid…
Abstract Number: 1209 • 2013 ACR/ARHP Annual Meeting
Starting Time Of Inflammatory Attacks In Patients With Familial Mediterranean Fever
Feyza Berktas¹, Nilufer Alpay Kanitez¹, Bahtiyar Toz¹, Oguz Kaan Bakkaloglu¹, Burak Erer² and Ahmet Gul¹, ¹Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Rheumatology Division, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
Background/Purpose: Familial Mediterranean fever (FMF), the most common form of the hereditary autoinflammatory diseases, is characterized by recurrent self-limiting attacks of fever and/or serositis accompanied…
Abstract Number: 96 • 2013 ACR/ARHP Annual Meeting
Epidemiology and Health Services Use For Osteoarthritis By First Nations People In Alberta, Canada
Cheryl Barnabe¹, Allyson Jones², Ed Enns³, Don Voaklander⁴, Christine Peschken⁵, Joanne Homik⁴, John Esdaile⁶, Sasha Bernatsky⁷, Brenda Hemmelgarn⁸ and Deborah Marshall⁹, ¹Medicine, Community Health Sciences, University of Calgary, Calgary, AB, Canada, ²Department of Physical Therapy, University of Alberta, Edmonton, AB, Canada, ³Alberta Bone and Joint Health Institute, Calgary, AB, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ⁶Medicine, University of British Columbia, Vancouver, BC, Canada, ⁷Clinical Epidemiology, Research Institute of the McGill University Health Ctre, Montreal, QC, Canada, ⁸Division of Nephrology, University of Calgary, Calgary, AB, Canada, ⁹University of Calgary, Calgary, AB, Canada
Background/Purpose: Self-reported survey data and a single provincial administrative data source have previously indicated that the First Nations (FN) population in Canada has a 1.5…
Abstract Number: 2759 • 2013 ACR/ARHP Annual Meeting
Can RA Registries Provide Contextual Safety Data For Modern RCTs?
Kaleb Michaud¹, Johan Askling², Hisashi Yamanaka³, Deborah Symmons⁴, Marie Holmqvist², Thomas Frisell⁵, George Reed⁶, Dimitrios A. Pappas⁷, Eiichi Tanaka⁸, Eisuke Inoue⁹, Suzanne M.M. Verstappen⁴, Christopher Garwood⁴, Laura Horne¹⁰, Kathy Lampl¹¹, Niklas Berglind¹², Stefan Franzen¹², Fredrik Nyberg¹³, Trung Tran¹⁴, Meilien Ho¹⁵ and Jeffrey D. Greenberg¹⁶, ¹Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, ²Karolinska Institutet, Stockholm, Sweden, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁵Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁶Orthopedics, University of Massachusetts Medical School, Worcester, MA, ⁷Columbia University, New York, NY, ⁸Tokyo Women's Medical University, Tokyo, Japan, ⁹Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ¹⁰AstraZeneca, Wilmington, DE, ¹¹AstraZeneca R&D Wilmington, Wilmington, DE, ¹²AstraZeneca R&D Mölndal, Mölndal, Sweden, ¹³AstraZeneca R&D, Mölndal, Sweden, ¹⁴MedImmune LLC, Gaithersburg, MD, ¹⁵AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ¹⁶New York University School of Medicine, New York, NY
Background/Purpose: For ethical reasons, modern phase-III RCTs in rheumatoid arthritis (RA) have limited placebo exposure time, resulting in uncertainties when interpreting low frequency adverse events…
Abstract Number: 1052 • 2013 ACR/ARHP Annual Meeting
Glucocorticosteroids and Mortality Risk In Rheumatoid Arthritis – Results Of a Population Based Study
Diane Lacaille¹, J. Antonio Avina-Zubieta^2,3, Eric C. Sayre², Michal Abrahamowicz⁴ and John Esdaile^1,5, ¹Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, ²Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁵Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Glucocorticosteroids (GC) are frequently used in the management of rheumatoid arthritis (RA). Due to their metabolic and immunosuppressive effects, they could increase the risk…
Abstract Number: 2682 • 2013 ACR/ARHP Annual Meeting
Incidence Trends and Predictors Of Orthopedic Surgery In Patients With Rheumatoid Arthritis – Results From a Well Defined Population
Korosh Hekmat¹, Lennart Jacobsson², Jan-Åke Nilsson³, Minna Willim⁴, Martin Englund⁵, Ingemar F. Petersson⁶ and Carl Turesson², ¹Department of Clinical Sciences, Section of Rheumatology, Malmö, Lund University, Malmö, Sweden, ²Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Department of Clinical Sciences Malmö, Section of Rheumatology, Lund University, Malmö, Sweden, ⁵Department of Orthopedics, Clinical Sciences Lund,, Lund University, Lund, Sweden, ⁶Musculoskeletal Scienes, Department of Orthopedics, Clinical Sciences, Lund, Sweden
Background/Purpose: Orthopedic surgery is used effectively in many patients with severe rheumatoid arthritis (RA). The aim of modern pharmacologic treatment is to prevent joint destruction…
Abstract Number: 1067 • 2013 ACR/ARHP Annual Meeting
Incidence and Prevalence Of Systemic Lupus Erythematosus: A 2010 Nation-Wide Population-Based Study Using French National Administrative Databases
Laurent Arnaud¹, Jean-Paul Fagot², Michel Païta², Alexis Mathian³, Anne Fagot-Campagna² and Zahir Amoura⁴, ¹Internal Medicine, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ²Caisse Nationale d’Assurance Maladie des Travailleurs Salariés, Paris, France, ³Internal Medicine Dpt 2, Pitié-Salpêtrière Hospital, APHP, Paris, France, ⁴Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France
Background/Purpose: To date, only a small number of studies have examined the epidemiology of systemic lupus erythematosus (SLE) on a nation-wide basis. These studies were…
Abstract Number: 2661 • 2013 ACR/ARHP Annual Meeting
Physical Activity, Adiposity, and The Risk Of Gout In Women: The Nurses Health Study
Hyon Choi^1,2,3, Lindsay C Burns^4,5, Yuqing Zhang⁶, Sharan Rai¹ and Gary Curhan⁷, ¹Arthritis Research Centre of Canada, Richmond, BC, Canada, ²Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Research, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁵Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada, ⁶Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁷German Research Center for Environmental Health, Harvard Medical School, Boston, MA
Background/Purpose: There is a remarkable, increasing disease burden of gout and its associated cardiovascular (CV)-metabolic comorbidities in the US. While the benefits of physical exercise…
Abstract Number: 1071 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Systemic Lupus Erythematosus and Lupus Nephritis In The United States: Analysis Of Commercial and Public Insurance Billing Data
Kunal Gandhi¹, Evo Alemao¹, Hugh Kawabata¹ and Jan L. Hillson², ¹Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Seattle, WA
Background/Purpose: Prevalence estimates of Systemic Lupus Erythematosus (SLE) in the U.S. vary, with numbers ranging from 161,000 (Helmick, 2008) to 1.5 million (Lupus Foundation of…
Abstract Number: 2578 • 2013 ACR/ARHP Annual Meeting
Pulmonary Hypertension In Systemic Sclerosis: Clinical Classification and Pulmonary Hypertension Subtypes
Monica Mohile¹, Mary Lucas², Virginia D. Steen³, Thomas A. Medsger Jr.⁴ and Robyn T. Domsic⁵, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ³Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ⁴Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Pumonary hypertension (PH) is a significant complication of systemic sclerosis (SSc), with prevalence reports of 10-25%. Predictors of PH remain somewhat elusive. Our…
Abstract Number: 1036 • 2013 ACR/ARHP Annual Meeting
The Independent Impact Of Depression On Incident Myocardial Infarction In Psoriatic Disease: A Population-Based Cohort Study
Lindsay C Burns^1,2, Jan P. Dutz¹ and Hyon Choi^3,4,5, ¹Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada, ²Research, Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Psoriasis (PsC) and psoriatic arthritis (PsA) represent common, lifelong inflammatory diseases of the skin and joints (respectively) that are associated with substantial cardiovascular and…
Abstract Number: 2477 • 2013 ACR/ARHP Annual Meeting
Impact Of Stressful Life Events On Disease Activity In Spondyloarthritis: Results Of The Coenv-2 Prospective Cohort Study
Guanguan Luo¹, Pierre Yves Boelle¹, Clément Turbelin¹, Roula Said Nahal², Nadine Zeboulon³, Maria-Antonietta d'Agostino⁴, Solen Kerneis¹, Thomas Hanslik^1,5 and Maxime A. Breban^4,6, ¹Epidemiology-UMR S 707, Faculté de Médecine Pierre et Marie Curie, Paris, France, ²Service de Rhumatologie, Hopital Ambroise Pare, Boulogne-Billancourt, France, ³Rheumatology, Ambroise Paré Hospital, Boulogne-Billancourt, France, ⁴Rheumatology, Ambroise Paré Hospital, and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ⁵Internal Medicine, Ambroise Paré Hospital, and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ⁶Immunology, NSERM U1016 - CNRS (UMR 8104), Montigny le Bretonneux, France
Background/Purpose: The relative contribution of environmental factors to triggering and/or progression of spondyloarthritis (SpA) remains poorly characterized. A link between disease activity and stressful life…
Abstract Number: 1037 • 2013 ACR/ARHP Annual Meeting
Incidence Of Malignancy In Patients With Rheumatoid Arthritis From a Japanese Large Observational Cohort (NinJa)
Atsushi Hashimoto¹, Noriyuki Chiba², Jinju Nishino³, Toshihiro Matsui⁴ and Shigeto Tohma⁵, ¹Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ²Department of Rheumatology, Morioka National Hospital, NHO, Iwate, Japan, ³Nishino Clinic, Orthopedics and Rheumatology, Tokyo, Japan, ⁴Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, Kanagawa, Japan, ⁵Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan
Background/Purpose :Patients with rheumatoid arthritis (RA) die mainly of cardiovascular/cerebrovascular diseases, respiratory diseases, infections, or malignancies. In recent years, the ratio of infections and respiratory…
Abstract Number: 2402 • 2013 ACR/ARHP Annual Meeting
Association Between Life Events and Rheumatoid Arthritis, Results From The EIRA Case Control Study
Annmarie Wesley¹, Camilla Camilla Bengtsson¹, Marie Holmqvist², Töres Theorell³, Saedis Saevarsdottir⁴, Eva Skillgate¹, Lars Klareskog⁵, Lars Alfredsson⁶ and Sara Wedrén⁷, ¹Institute of Enviornmental Medicine, Karolinska Insitutet, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Public Health Sciences, Karolinska Insitutet, Stockholm, Sweden, ⁴Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ⁵Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁶Institute of Enviornmental Medicine/Cardiovascular epidemiology, Karolinska Insitutet, Stockholm, Sweden, ⁷Rheumatology unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The association between life events and rheumatoid arthritis (RA) has previously been studied with contradicting results. No previous study have investigated the impact of…
Abstract Number: 1047 • 2013 ACR/ARHP Annual Meeting
Rates Of Hospitalized Infections In Rheumatoid Arthritis Patients From 5 Rheumatoid Arthritis Registries Across The World
Hisashi Yamanaka¹, Johan Askling², Niklas Berglind³, Stefan Franzén³, Thomas Frisell⁴, Christopher Garwood⁵, Jeffrey D. Greenberg⁶, Meilien Ho⁷, Marie Holmqvist², Laura Horne⁸, Eisuke Inoue¹, Kathy Lampl⁹, Kaleb Michaud¹⁰, Dimitrios A. Pappas¹¹, George Reed¹², Deborah Symmons⁵, Eiichi Tanaka¹³, Trung Tran¹⁴, Suzanne Verstappen⁵ and Fredrik Nyberg¹⁵, ¹Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ²Karolinska Institutet, Stockholm, Sweden, ³AstraZeneca R&D Mölndal, Mölndal, Sweden, ⁴Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁶New York Hospital for Joint Disease, New York, NY, ⁷AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ⁸AstraZeneca, Wilmington, DE, ⁹AstraZeneca R&D Wilmington, Wilmington, DE, ¹⁰University of Nebraska Medical Center, Omaha, NE, ¹¹Columbia University, New York, NY, ¹²University of Massachusetts Medical School, Worcester, MA, ¹³Tokyo Women's Medical University, Tokyo, Japan, ¹⁴MedImmune LLC, Gaithersburg, MD, ¹⁵AstraZeneca R&D, Mölndal, Sweden
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk of infection due to both RA itself and immunomodulating treatments. Infection rates are often difficult to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].